Filter Results:
(3,178)
Show Results For
- All HBS Web
(3,178)
- People (7)
- News (429)
- Research (2,362)
- Events (1)
- Multimedia (5)
- Faculty Publications (1,941)
Show Results For
- All HBS Web
(3,178)
- People (7)
- News (429)
- Research (2,362)
- Events (1)
- Multimedia (5)
- Faculty Publications (1,941)
- Profile
Yaping Wang
"I wanted a job in an industry instead of a PhD." For more than eight years, Yaping worked for Mars in Beijing, conducting research for product innovation. "I probed for consumer insights, then helped translate those... View Details
- Web
Innovating at Scale - Course Catalog
benefits and disadvantages of alliances Class 11: How to develop and run a corporate venture capital fund Class 12: When and how to partner with startups Class 13: When and how to partner with customers Class 14: Summary and panel on careers Scope: Spans multiple View Details
- 01 Apr 2002
- News
Charting the Luminary Leadership in Professional Service Firms
of the factors that drive success in an industry that attracts 65 percent of MBA graduates from leading business schools — many of whom eventually leave to run organizations of their own. With revenues approaching a trillion dollars,... View Details
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Biotechnology Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- 23 Jul 2013
- First Look
First Look: July 23
School Case 713-483 Yammer (B) Supplement to "Yammer (A)," HBS case 713-407 Purchase this case: http://hbr.org/search/713483-PDF-ENG Harvard Business School Case 712-466 Moving to Universal Coverage: Health Care Reform in... View Details
Keywords: Anna Secino
- 12 Dec 2006
- First Look
First Look: December 12, 2006
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=607010 Note on Health Savings Accounts, Flexible Spending Accounts, and Health Reimbursement Account Vendors Harvard Business School Note... View Details
Keywords: Martha Lagace
- December 2021
- Article
India's Food Supply Chain during the Pandemic
By: Matt Lowe, G.V. Nadhanael and Benjamin N. Roth
We document the impact of India’s COVID-19 lockdown on the food supply chain. Food arrivals in wholesale markets dropped by 69% in the three weeks following the lockdown and wholesale prices rose by 8%. Six weeks after the lockdown began, volumes and prices had fully... View Details
Keywords: COVID-19; Supply Chain; Health Pandemics; Food; Policy; System Shocks; Food and Beverage Industry; India
Lowe, Matt, G.V. Nadhanael, and Benjamin N. Roth. "India's Food Supply Chain during the Pandemic." Art. 102162. Food Policy 105 (December 2021).
- January 2003 (Revised May 2003)
- Case
Heineken NV: Workplace HIV/AIDS Programs in Africa (A)
This case is the first in a three-part series that explores the multifaceted organizational and strategic choices that companies now face as a result of the global AIDS epidemic. Heineken is considering becoming one of the first companies to offer AIDS drugs... View Details
Keywords: Health Disorders; Corporate Social Responsibility and Impact; Employees; Food and Beverage Industry; Africa
Barrett, Diana, and Daniella Ballou. "Heineken NV: Workplace HIV/AIDS Programs in Africa (A)." Harvard Business School Case 303-063, January 2003. (Revised May 2003.)
- 10 Apr 2006
- Research & Ideas
American Auto’s Troubled Road
For decades, the U.S. auto industry ruled America's economy, shaped the country's development, and influenced American culture and social mores. Now, buffeted by globalization and other powerful forces, it faces a moment of truth. The... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- November 1978 (Revised October 1989)
- Case
Amicon Corp. (B)
Details the negotiation between Amicon and three potential licensees, Jackson, Maynard-Smith and Behrstein. View Details
Keywords: Technology; Patents; Negotiation Process; Negotiation Participants; Health Care and Treatment; Biotechnology Industry
Capon, Noel. "Amicon Corp. (B)." Harvard Business School Case 579-094, November 1978. (Revised October 1989.)
- August 2010 (Revised August 2012)
- Supplement
Generation Health: A Pioneer in Genetics Benefit Management (B)
By: Robert F. Higgins
Higgins, Robert F. "Generation Health: A Pioneer in Genetics Benefit Management (B)." Harvard Business School Supplement 811-005, August 2010. (Revised August 2012.)
- June 9, 2023
- Article
A Radical Treatment for Insulin Pricing
By: Leemore S. Dafny
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details
Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Dafny, Leemore S. "A Radical Treatment for Insulin Pricing." New England Journal of Medicine 386, no. 23 (June 9, 2023): 2157–2159.
- 01 Oct 2002
- News
Making a Difference
the globe to put their skills to work on issues related to the environment, education, the arts, health care, poverty, and economic development. In the United States, fellows worked in diverse organizations such as the National Campaign... View Details
- 2003
- Chapter
La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971
By: Arthur A. Daemmrich
- 01 Jun 2017
- News
The Exchange: Venture Forth
illustration by Peter Arkle When Professor Paul Gompers began studying the venture capital industry in the late 1980s, colleagues often wondered why. “They’d say that it’s such a backwater and unimportant industry,” he recalls. With more... View Details
Keywords: April White
- 01 Jun 2015
- News
Ask the Expert: The Kids Are All Right
has not yet been chosen—industries where all the brands are perceived as the same. (Here, think financial services, health care, and retail.) These industries are most at risk for disruption by this... View Details
- 23 Feb 2009
- Research & Ideas
Creative Entrepreneurship in a Downturn
formation, and innovation. He is also a partner of the international management consulting firm McKinsey & Company, where he is a leader of its Innovation practice. Chakravorti has advised over 30 Fortune 500 companies on innovation, growth, and new... View Details
Keywords: by Martha Lagace
- March 2011
- Teaching Note
PrimedicProviding Primary Care in Mexico (TN)
Teaching Note for 811040. View Details
- 13 May 2014
- First Look
First Look: May 13
how management and corporate boards of directors can best manage investor relations with activist stockholders such as hedge funds who are demanding major changes within a corporation to improve stockholder return. Beverage industry firm... View Details
Keywords: Sean Silverthorne